Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd

The company maintains a strong liquidity position, with a current ratio of 3.44, indicating that it has more than three times the current assets to cover its current liabilities. Its price-to-book ratio of 1.94 and price-to-tangible-book ratio of 1.94 suggest that the market values the company at a premium to its book value, but not excessively so. The debt-to-equity ratio of 0.06 indicates a conservative capital structure, with minimal reliance on debt financing. In terms of profitability, the company's return on equity (ROE) of 5.71% and return on assets (ROA) of 4.14% are below the typical thresholds for high-performing pharmaceutical firms, suggesting that the company is generating moderate returns relative to its equity and asset base. The gross profit margin of 51.85% (calculated as gross profit divided by revenue) is in line with industry norms, but the operating margin of 9.65% (operating income divided by revenue) is relatively low, indicating potential inefficiencies in cost management or pricing power. The company's revenue is concentrated in a single geographic market, primarily China, with no disclosed international operations. This concentration increases exposure to local economic and regulatory risks, including changes in healthcare policy and reimbursement rates. The company does not report segment-level revenue, so it is unclear whether it operates multiple product lines or therapeutic areas. Looking ahead, the company's revenue is projected to grow by a modest amount in the current fiscal year, with a slight acceleration expected in the following year. However, the exact numeric deltas are not disclosed in the available data. The company's free cash flow of 46.54 million CNY and operating cash flow of 63.01 million CNY indicate that it generates sufficient cash to support operations and potentially fund growth initiatives. The risk assessment highlights a medium liquidity risk, primarily due to the company's negative net cash position after accounting for total debt. While the company's dilution risk is currently low, the risk assessment does not provide a detailed breakdown of potential dilution sources or their likelihood. The company's capital expenditures are negative, suggesting that it is reducing its investment in physical assets, which could indicate a focus on cost control or a shift in strategic priorities. Recent events, including filings and transcripts, are not detailed in the available data, so it is unclear whether the company has announced new products, partnerships, or strategic initiatives that could impact its future performance.